International Biotechnology (LON:IBT) Stock Price Crosses Above 200-Day Moving Average – What’s Next?

International Biotechnology (LON:IBT) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 684.42 ($8.38) and traded as high as GBX 703.25 ($8.61). International Biotechnology shares last traded at GBX 702 ($8.59), with a volume of 145,383 shares changing hands.

International Biotechnology Stock Performance

The business’s fifty day simple moving average is GBX 695.23 and its 200-day simple moving average is GBX 684.42. The firm has a market cap of £260.95 million, a P/E ratio of 1,470.90 and a beta of 0.21. The company has a current ratio of 0.46, a quick ratio of 0.32 and a debt-to-equity ratio of 9.66.

International Biotechnology Increases Dividend

The firm also recently announced a dividend, which will be paid on Friday, January 24th. Investors of record on Thursday, December 19th will be paid a GBX 15.56 ($0.19) dividend. The ex-dividend date of this dividend is Thursday, December 19th. This is a boost from International Biotechnology’s previous dividend of $14.50. This represents a dividend yield of 2.21%. International Biotechnology’s dividend payout ratio (DPR) is presently 6,041.67%.

Insider Activity at International Biotechnology

In related news, insider Katherine Cornish-Bowden purchased 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 17th. The shares were acquired at an average price of GBX 713 ($8.73) per share, for a total transaction of £10,695 ($13,090.58). 4.18% of the stock is owned by company insiders.

International Biotechnology Company Profile

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.

The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.